Efficacy and safety of vaccination of the influenza A (H5N1) Egyptian strain, and searching for the optimal intervals of the primary vaccination. - Efficacy and safety of vaccination of the influenza A(H5N1) Egyptian strain, and searching for the optimal intervals of the primary vaccination. (H5N1_Egypt interval)

Clinical Research Center, National Hospital Organization0 sites140 target enrollmentSeptember 18, 2013

Overview

No summary available.

Registry

who.int

Start Date

September 18, 2013

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Clinical Research Center, National Hospital Organization

•1\) Individuals with the history of Avian Influenza A (H5N1\) virus infection. (obtained from subjects) 2\) Individuals, who had history of anaphylaxis to foods or medicines previously. 3\) Individuals with severe diseases in cardiovascular, blood, respiratory, liver, kidney, digestive or neurological systems in their clinical recording. 4\) Individuals with a history of acute disseminated encephalomyelitis and Guillain\-Barre syndrome in the past. 5\) Individuals participated in a clinical trial within four months (counted from the date of vaccination). 6\) Individuals vaccinated with live vaccine within 27 days, or received a dose of inactivated vaccine within six days (including the day of vaccination). 7\) Individuals received with gamma globulin or blood transfusion within three months, or received the formulation of high dose of gamma globulin therapy (200 mg/kg or more) within six months (including the day of vaccination). 8\)Individuals who are deemed to be inappropriate by the investigator.